These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31270220)

  • 1. Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.
    Ford JH; Ayer DW; Zhang Q; Carter JN; Leroux E; Skljarevski V; Aurora SK; Tockhorn-Heidenreich A; Lipton RB
    Neurology; 2019 Jul; 93(5):e508-e517. PubMed ID: 31270220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).
    Ford J; Tassorelli C; Leroux E; Wang S; Ayer D; Nichols R; Detke H
    Qual Life Res; 2021 Jan; 30(1):105-115. PubMed ID: 32930994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
    Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
    JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
    Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study.
    Ford JH; Stauffer VL; McAllister P; Akkala S; Sexson M; Ayer DW; Wang S
    Qual Life Res; 2021 Feb; 30(2):455-464. PubMed ID: 32944843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
    Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
    J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
    Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
    Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
    Ailani J; Andrews JS; Rettiganti M; Nicholson RA
    J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.
    Varnado OJ; Ye W; Mi X; Burge R; Hall J
    J Med Econ; 2023; 26(1):149-157. PubMed ID: 36601798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
    Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
    Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.
    Stauffer VL; Wang S; Voulgaropoulos M; Skljarevski V; Kovacik A; Aurora SK
    Headache; 2019 Jun; 59(6):834-847. PubMed ID: 30942898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
    Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
    Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
    Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
    Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
    Detke HC; Millen BA; Zhang Q; Samaan K; Ailani J; Dodick DW; Aurora SK
    Headache; 2020 Feb; 60(2):348-359. PubMed ID: 31710104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).
    Tepper SJ; Ailani J; Ford JH; Nichols RM; Li LQ; Kemmer P; Hand AL; Tockhorn-Heidenreich A
    Clin Drug Investig; 2022 Mar; 42(3):263-275. PubMed ID: 35041159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
    Förderreuther S; Zhang Q; Stauffer VL; Aurora SK; Láinez MJA
    J Headache Pain; 2018 Dec; 19(1):121. PubMed ID: 30594122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
    Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
    J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.
    Ruff DD; Ford JH; Tockhorn-Heidenreich A; Stauffer VL; Govindan S; Aurora SK; Terwindt GM; Goadsby PJ
    Eur J Neurol; 2020 Apr; 27(4):609-618. PubMed ID: 31692188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.